新阿尔茨海默氏药物TML-6 开始全球试验 目标是一条新途径 Taiwan's Merry Life Biomedical begins global trial for new Alzheimer's drug TML-6, targeting a novel pathway.

台湾一家生物技术公司Merry Life生物医学已开始全球第二阶段的TML-6试验,TML-6是早期阿尔茨海默氏病的新药。 A Taiwan-based biotech company, Merry Life Biomedical, has started a global Phase II trial for TML-6, a new drug for early-stage Alzheimer's disease. TML-6采用独特的多目标方法,包括抗氧化效应和抗炎效应,来防治阿尔茨海默氏病。 TML-6 uses a unique multi-target approach, including anti-oxidative and anti-inflammatory effects, to combat Alzheimer's. 上一期试验表明,该药物是安全的,并且是良好的。 Previous Phase I trials showed the drug is safe and well-tolerated. 第二阶段试验将涉及美国、瑞典和台湾19个地点的210名有轻度认知障碍或轻度痴呆的病人。 The Phase II trial will involve 210 patients with mild cognitive impairment or mild dementia across 19 sites in the U.S., Sweden, and Taiwan. 这是第一种针对自体健康路径的药物, 为阿尔茨海默氏病人带来新的希望。 This is the first drug to target the autolysosome pathway, offering new hope for Alzheimer's patients.